Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype
about
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversalOvercoming cisplatin resistance by mTOR inhibitor in lung cancer.Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug actionSynergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformansHypoxia as a target for drug combination therapy of liver cancer.Rapamycin selectively reduces the association of transcripts containing complex 5' UTRs with ribosomes in C4-2B prostate cancer cells.Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.Calcineurin is essential for survival during membrane stress in Candida albicans.Immunosuppressive interactions among calcium channel antagonists and selected corticosteroids and macrolides using human whole blood lymphocytes.Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramPhase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoproteinAssociations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients.Rapid Identification of Chemoresistance Mechanisms Using Yeast DNA Mismatch Repair Mutants.Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infectionTargeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac ToxicityPredicted mechanisms of resistance to mTOR inhibitors.Platelet activating factor synthesis and metabolism in intestinal ischaemia-reperfusion injury.Functional expression of P-glycoprotein in Saccharomyces cerevisiae confers cellular resistance to the immunosuppressive and antifungal agent FK520.Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expressionInhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.Exposure-response relationships and drug interactions of sirolimusSynergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo.Targeting the autophagy pathway using ectopic expression of Beclin 1 in combination with rapamycin in drug-resistant v-Ha-ras-transformed NIH 3T3 cells.Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells.Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils.Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters.Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin.Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.FK506 and Cyclosporin A Enhance IL-6 Production in Monocytes: A single-Cell Assay.FK506 Attenuates the MRP1-Mediated Chemoresistant Phenotype in Glioblastoma Stem-Like Cells
P2860
Q21246014-79185149-D48B-4E26-917B-D330F87B2BB5Q24815638-14B765F9-581E-4517-B043-B1F49B387CA3Q28343624-EA02E7F4-EC37-45EA-8B2D-E1171A732B8AQ28343929-869EE49B-73FF-468D-A070-9BEFCCA6FA47Q30491780-579E53F4-3C73-4D75-96DA-98F372B6CCA5Q34033097-E1D24269-77C5-4A0C-88BA-C9FEE9F2DC29Q34052899-281904FC-8F86-40D0-8946-153A8A32F477Q34085830-C9F9606B-1812-4E8F-AEB0-901C2E932BA5Q34260591-999ABF49-94FF-4745-8B0D-D763B128BB0AQ34414736-A3B4FD1F-7D1C-4A6A-85A4-DA59395A985BQ35187824-70EA258B-7E8D-415A-827F-8B4751AEF7CFQ35613163-18B7B673-27B3-4CAC-9D3F-D3BB866BB439Q35704726-281BB23F-22A9-4016-8CEA-55DD94B64523Q35746053-F567ED40-5F5A-45E4-9AC4-5656567F071CQ35999766-E608EA93-57CF-40D0-B628-F4AFA9C6EB19Q36585744-CAD24530-37FB-4F87-B07A-26FF17C4B6BDQ36627635-D5DDA212-2857-4D20-BDAA-D723E6001EB2Q36643297-77378F2F-0199-4D1A-A351-689837E2F3EAQ36765105-DB0E5A28-5013-4FB1-8E36-E33AAC952DE5Q36899877-6B9BA25D-D576-4D12-9A77-FAD4E8FA2236Q37361711-2BFA6EC9-E7DE-4B6A-999F-C69A8E04D1F3Q37401525-6400AD12-2C3B-4E39-AC0F-EB7610920A1CQ37599431-23D391B4-7946-4A22-BEE9-934BFA7A8734Q37636860-B20A727B-ACC3-44B4-8ABC-9227754FAF32Q39558233-66916F38-410A-4616-A982-1E4CE1B1BE57Q39746465-1FE0AA41-02A0-4FEA-84DA-CA188CCD2FC6Q39785007-0A32622E-EA8B-4BFE-9334-5217157C2C2FQ39967534-6DC25647-C7C6-4B3E-849E-45E005D5A204Q41807884-4F834F09-FEDF-4839-8E7A-37999F8B22BCQ58749539-C87EDB3C-FB52-4C8A-A355-8656C2DB7BB3
P2860
Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Immunosuppressants FK506 and r ...... multidrug resistance phenotype
@ast
Immunosuppressants FK506 and r ...... multidrug resistance phenotype
@en
Immunosuppressants FK506 and r ...... multidrug resistance phenotype
@nl
type
label
Immunosuppressants FK506 and r ...... multidrug resistance phenotype
@ast
Immunosuppressants FK506 and r ...... multidrug resistance phenotype
@en
Immunosuppressants FK506 and r ...... multidrug resistance phenotype
@nl
prefLabel
Immunosuppressants FK506 and r ...... multidrug resistance phenotype
@ast
Immunosuppressants FK506 and r ...... multidrug resistance phenotype
@en
Immunosuppressants FK506 and r ...... multidrug resistance phenotype
@nl
P2093
P1433
P1476
Immunosuppressants FK506 and r ...... multidrug resistance phenotype
@en
P2093
B E Bierer
K Stieglitz
R J Arceci
P304
P407
P577
1992-09-15T00:00:00Z